Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of switching from bulevirtide to brelovitug for treating chronic hepatitis Delta infection CHD in this Phase 2b3, randomized, open-label, multicenter clinical trial. The study compares continuing bulevirtide before switching to brelovitug against an immediate switch to brelovitug in adults with CHD. This research aims to better understand treatment options for managing this condition. Participants are assigned to one of two groups one group switches immediately to brelovitug 300 mg once weekly for 96 weeks, while the other group continues bulevirtide daily before switching to brelovitug 300 mg once weekly for 72 weeks. Both treatments are administered as injections under the skin. The study includes a treatment period lasting up to 96 weeks, during which participants receive their assigned medication schedule. During the trial, participants undergo various assessments including measurement of HDV RNA levels to evaluate viral response, monitoring of liver function tests such as ALT, and evaluation of liver stiffness and clinical disease progression. Safety is monitored by tracking treatment-emergent adverse events and reasons for treatment discontinuation up to Week 96. The main outcome is the proportion of participants achieving undetectable HDV RNA at Week 24. The total study duration extends through treatment and post-treatment follow-up periods lasting up to several years.